Metformin
- Generic Name
- Metformin
- Brand Names
- Actoplus Met, Avandamet, Fortamet, Glucophage, Glucovance, Glumetza, Glycon, Invokamet, Janumet, Jentadueto, Kazano, Kombiglyze, Komboglyze, Qternmet, Riomet, Segluromet, Synjardy, Trijardy, Velmetia, Xigduo
- Drug Type
- Small Molecule
- Chemical Formula
- C4H11N5
- CAS Number
- 657-24-9
- Unique Ingredient Identifier
- 9100L32L2N
- Background
Metformin is a biguanide antihyperglycemic agent and first-line pharmacotherapy used in the management of type II diabetes.
...
- Indication
Metformin immediate-release formulations
Metformin is indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients ≥10 years old with type 2 diabetes mellitus.
Metformin extended-release tablet (XR)
...
- Associated Conditions
- Cardiovascular Mortality, End Stage Renal Disease (ESRD), Hospitalizations, Polycystic Ovarian Syndrome (PCOS), Type 2 Diabetes Mellitus, Decreased estimated glomerular filtration rate
- Associated Therapies
- -
A Safety and Feasibility Trial Protocol of Metformin in Infants After Perinatal Brain Injury
- Conditions
- Interventions
- First Posted Date
- 2024-05-24
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Boston Children's Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT06429007
Fish Oil, Metformin and Heart Health in PCOS
- Conditions
- Interventions
- First Posted Date
- 2024-05-22
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- University of Alberta
- Target Recruit Count
- 146
- Registration Number
- NCT06424860
A Study to Assess the Effect of Povorcitinib on Digoxin, Rosuvastatin, and Metformin Pharmacokinetics and the Effect of Probenecid on Povorcitinib Pharmacokinetics When Administered Orally to Healthy Adult Participants
- Conditions
- Interventions
- First Posted Date
- 2024-05-16
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 72
- Registration Number
- NCT06416800
- Locations
- 🇺🇸
Fortrea Clinical Research Unit, Dallas, Texas, United States
Metformin in Patients With Unruptured Vertebrobasilar Dissecting Aneurysms (METTLE)
- Conditions
- Interventions
- First Posted Date
- 2024-05-09
- Last Posted Date
- 2024-08-05
- Lead Sponsor
- Ming Lv
- Target Recruit Count
- 60
- Registration Number
- NCT06405971
- Locations
- 🇨🇳
Beijing Tiantan Hospital, Beijing, Beijing, China
Adjuvant Therapy With Letrozole in Induction of Ovulation With Polycystic Ovarian Syndrome
- Conditions
- Interventions
- First Posted Date
- 2024-05-08
- Last Posted Date
- 2024-05-08
- Lead Sponsor
- Beni-Suef University
- Target Recruit Count
- 500
- Registration Number
- NCT06405178
- Locations
- 🇪🇬
Beni-suef university Hospital, Banī Suwayf, Egypt
Remote Cognitive Assessment and Wearable Device While Assessing the Impact of Metformin in Patients With History of Cranial Radiation Therapy
- First Posted Date
- 2024-04-22
- Last Posted Date
- 2024-06-28
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 100
- Registration Number
- NCT06377696
- Locations
- 🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States
Metformin Treatment of Patients With Hand Osteoarthritis
- First Posted Date
- 2024-04-16
- Last Posted Date
- 2024-08-16
- Lead Sponsor
- Marius Henriksen
- Target Recruit Count
- 150
- Registration Number
- NCT06367283
- Locations
- 🇩🇰
The Parker Institute, Bispebjerg and Frederiksberg hospital, Copenhagen, Frederiksberg, Denmark
Metformin and Esomeprazole in Preterm Pre-eclampsia
- Conditions
- Interventions
- First Posted Date
- 2024-04-11
- Last Posted Date
- 2024-04-11
- Lead Sponsor
- Christiana Care Health Services
- Target Recruit Count
- 4
- Registration Number
- NCT06359015
- Locations
- 🇺🇸
Christianacare Health System, Newark, Delaware, United States
Chemoradiotherapy With or Without Metformin in Locally Advanced Cervical Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-04-08
- Last Posted Date
- 2024-04-08
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 51
- Registration Number
- NCT06353061
Efficacy and Safety of Semaglutide Injection in Subjects With Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2024-04-01
- Last Posted Date
- 2024-04-01
- Lead Sponsor
- Chengdu Brilliant Pharmaceutical Co., Ltd.
- Target Recruit Count
- 478
- Registration Number
- NCT06339086
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.